Shares of Orexigen (OREX -4.8%) slip deeper into the red today after it reported a Q4 that beat on a per share basis, but came up short on revenue. The company reported a loss of $0.41 per share, versus the consensus of a $0.44 per share loss. Revenues were $857K, below analyst estimates of $890K. Total operating expenses were significantly higher for the quarter, coming in at $33.3M compared to $5.2M in Q411, reflecting higher R&D expenses associated with the conduct of its Contrave cardiovascular outcomes trial. Read more on earnings here: Earnings Call Transcript.